RKRajeshri G. Karki

Rajeshri G. Karki

*This is an algorithmically generated author record based on publicly available information.

Rajeshri G. Karki has a total of 263 co-authors. Here are the top co-authors by number of shared publications:

  • Guiqing Liang

    Pharmacokinetic Sciences, Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States

    5 shared publications
  • Christian Wiesmann

    Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland

    4 shared publications
  • Christopher M. Adams

    Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139, United States

    4 shared publications
  • Frederic Cumin

    Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4056 Basel, Switzerland

    4 shared publications
  • Mark Knapp

    Discovery Sciences, Biomedical Research, Novartis

    4 shared publications
  • Paul Ramage

    Novartis Institutes for BioMedical Research, Novartis Campus, CH-4056 Basel, Switzerland

    4 shared publications

Latest Publications

  • Open Access

    Discovery of EGT710, an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease Inhibitor

    by Julien P. N. Papillon, Jun Yuan, Matthew J. Hesse, Lei Zhang, Richard I. Robinson, Nathaniel F. Ware, Viktor Hornak, Rajeshri G. Karki, Tom Kirrane, Keira Garland, et al.

    The coronavirus main protease (3CLpro, Mpro, nsp5) is a highly conserved cysteine protease unique to the Coronaviridae family, including SARS-CoV-2, and is a validated target for the treatment of COVID-19. Our efforts focused on the identification of a nonpeptidomimetic Mpro inhibitor, due to the potential for superior pharmacological properties. Herein, we report our efforts leveraging virtual screening and X-ray crystallography that enabled a structure-based drug design approach, leading to the discovery of series of quinazoline-2,4(1H,3H)-dione and oxoimidazolidine-4-carbonitrile compounds with potent inhibition of SARS-CoV-2 Mpro as well as other coronaviruses main proteases. Extensive lead optimization focusing on pharmacokinetic properties, developability, and breadth of activity across coronaviruses, led to the identification of EGT710. EGT710 demonstrates excellent potency against SARS-CoV-2 infection in a primary differentiated normal human bronchial epithelial (dNHBE) cellular assay, as well as a favorable pharmacology profile that supported advancement into preclinical and clinical studies.


  • Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes

    by Simone Bonazzi, Audrey Gray, Noel M. Thomsen, Jonathan Biag, Nancy Labbe-Giguere, Erin P. Keaney, Hasnain A. Malik, Yingchuan Sun, Jill Nunez, Rajeshri G. Karki, et al.

    The allosteric inhibitor of the mechanistic target of rapamycin (mTOR) everolimus reduces seizures in tuberous sclerosis complex (TSC) patients through partial inhibition of mTOR functions. Due to its limited brain permeability, we sought to develop a catalytic mTOR inhibitor optimized for central nervous system (CNS) indications. We recently reported an mTOR inhibitor (1) that is able to block mTOR functions in the mouse brain and extend the survival of mice with neuronal-specific ablation of the Tsc1 gene. However, 1 showed the risk of genotoxicity in vitro. Through structure-activity relationship (SAR) optimization, we identified compounds 9 and 11 without genotoxicity risk. In neuronal cell-based models of mTOR hyperactivity, both corrected aberrant mTOR activity and significantly improved the survival rate of mice in the Tsc1 gene knockout model. Unfortunately, 9 and 11 showed limited oral exposures in higher species and dose-limiting toxicities in cynomolgus macaque, respectively. However, they remain optimal tools to explore mTOR hyperactivity in CNS disease models.


  • Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach

    by Edwige Lorthiois, James Roache, David Barnes-Seeman, Eva Altmann, Ulrich Hassiepen, Gordon Turner, Rohit Duvadie, Viktor Hornak, Rajeshri G. Karki, Nikolaus Schiering, et al.

    The serine protease factor XI (FXI) is a prominent drug target as it holds promise to deliver efficacious anticoagulation without an enhanced risk of major bleeds. Several efforts have been described targeting the active form of the enzyme, FXIa. Herein, we disclose our efforts to identify potent, selective, and orally bioavailable inhibitors of FXIa. Compound 1, identified from a diverse library of internal serine protease inhibitors, was originally designed as a complement factor D inhibitor and exhibited submicromolar FXIa activity and an encouraging absorption, distribution, metabolism, and excretion (ADME) profile while being devoid of a peptidomimetic architecture. Optimization of interactions in the S1, S1β, and S1′ pockets of FXIa through a combination of structure-based drug design and traditional medicinal chemistry led to the discovery of compound 23 with subnanomolar potency on FXIa, enhanced selectivity over other coagulation proteases, and a preclinical pharmacokinetics (PK) profile consistent with bid dosing in patients.


  • Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases

    by Nello Mainolfi, Takeru Ehara, Rajeshri G. Karki, Karen Anderson, Aengus Mac Sweeney, Sha-Mei Liao, Upendra A. Argikar, Keith Jendza, Chun Zhang, James Powers, et al.

    The alternative pathway (AP) of the complement system is a key contributor to the pathogenesis of several human diseases including age-related macular degeneration, paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and various glomerular diseases. The serine protease factor B (FB) is a key node in the AP and is integral to the formation of C3 and C5 convertase. Despite the prominent role of FB in the AP, selective orally bioavailable inhibitors, beyond our own efforts, have not been reported previously. Herein we describe in more detail our efforts to identify FB inhibitors by high-throughput screening (HTS) and leveraging insights from several X-ray cocrystal structures during optimization efforts. This work culminated in the discovery of LNP023 (41), which is currently being evaluated clinically in several diverse AP mediated indications.


  • Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors

    by Toshio Kawanami, Rajeshri G. Karki, Emma Cody, Qian Liu, Guiqing Liang, Gary M. Ksander, Dean F. Rigel, Nikolaus Schiering, Yongjin Gong, Gary M. Coppola, et al.

    Inhibition of neprilysin (NEP) is widely studied as a therapeutic target for the treatment of hypertension, heart failure, and kidney disease. Sacubitril/valsartan (LCZ696) is a drug approved to reduce the risk of cardiovascular death in heart failure patients with reduced ejection fraction. LBQ657 is the active metabolite of sacubitril and an inhibitor of NEP. Previously, we have reported the crystal structure of NEP bound with LBQ657, whereby we noted the presence of a subsite in S1′ that has not been explored before. We were also intrigued by the zinc coordination made by one of the carboxylic acids of LBQ657, leading us to explore alternative linkers to efficiently engage zinc for NEP inhibition. Structure-guided design culminated in the synthesis of selective, orally bioavailable, and subnanomolar inhibitors of NEP. A 17-fold boost in biochemical potency was observed upon addition of a chlorine atom that occupied the newly found subsite in S1′. We report herein the discovery and preclinical profiling of compound 13, which paved the path to our clinical candidate.


  • Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders

    by Simone Bonazzi, Carleton P. Goold, Audrey Gray, Noel M. Thomsen, Jill Nunez, Rajeshri G. Karki, Aakruti Gorde, Jonathan D. Biag, Hasnain A. Malik, Yingchuan Sun, et al.

    Recent clinical evaluation of Everolimus for seizure reduction in patients with Tuberous Sclerosis Complex (TSC), a disease with overactivated mTOR signaling, has demonstrated the therapeutic value of mTOR inhibitors for Central Nervous System (CNS) indications. Given that Everolimus is an incomplete inhibitor of mTOR function we sought to develop a new mTOR inhibitor that has improved properties and is suitable for CNS disorders. Starting from an in-house purine-based compound, optimization of the physicochemical properties of a thiazolopyrimidine series led to the discovery of the small molecule 7, a potent and selective brain penetrant ATP-competitive mTOR inhibitor. In neuronal cell-based models of mTOR hyperactivity, 7 corrected mTOR pathway activity and the resulting neuronal overgrowth phenotype. The new mTOR inhibitor 7 showed good brain exposure and significantly improved the survival rate of mice with neuronal-specific ablation of the Tsc1 gene. These results demonstrate the potential utility of this tool compound to test therapeutic hypotheses that depend on mTOR hyperactivity in the CNS.


  • Open Access

    Author Correction: Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex

    by Dirksen E. Bussiere, Lili Xie, Honnappa Srinivas, Wei Shu, Ashley Burke, Celine Be, Junping Zhao, Adarsh Godbole, Dan King, Rajeshri G. Karki, et al.

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  • Top Cited Papers

    Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex

    by Dirksen E. Bussiere, Lili Xie, Honnappa Srinivas, Wei Shu, Ashley Burke, Celine Be, Junping Zhao, Adarsh Godbole, Dan King, Rajeshri G. Karki, et al.

    The anticancer agent indisulam inhibits cell proliferation by causing degradation of RBM39, an essential mRNA splicing factor. Indisulam promotes an interaction between RBM39 and the DCAF15 E3 ligase substrate receptor, leading to RBM39 ubiquitination and proteasome-mediated degradation. To delineate the precise mechanism by which indisulam mediates the DCAF15–RBM39 interaction, we solved the DCAF15–DDB1–DDA1–indisulam–RBM39(RRM2) complex structure to a resolution of 2.3 Å. DCAF15 has a distinct topology that embraces the RBM39(RRM2) domain largely via non-polar interactions, and indisulam binds between DCAF15 and RBM39(RRM2), coordinating additional interactions between the two proteins. Studies with RBM39 point mutants and indisulam analogs validated the structural model and defined the RBM39 α-helical degron motif. The degron is found only in RBM23 and RBM39, and only these proteins were detectably downregulated in indisulam-treated HCT116 cells. This work further explains how indisulam induces RBM39 degradation and defines the challenge of harnessing DCAF15 to degrade additional targets.


  • Design, Synthesis, and Preclinical Characterization of Selective Factor D Inhibitors Targeting the Alternative Complement Pathway

    by Rajeshri G. Karki, James Powers, Nello Mainolfi, Karen Anderson, David B. Belanger, Donglei Liu, Nan Ji, Keith Jendza, Christine F. Gelin, Aengus Mac Sweeney, et al.

    Complement Factor D (FD), a highly specific S1 serine protease, plays a central role in the amplification of the alternative complement pathway (AP) of the innate immune system. Dysregulation of AP activity predisposes individuals to diverse disorders such as age-related macular degeneration (AMD), atypical hemolytic uremic syndrome (aHUS), membranoproliferative glomerulonephritis type II (MPGNII) and paroxysmal nocturnal hemoglobinuria (PNH). Previously, we have reported the screening efforts and identification of reversible benzylamine-based FD inhibitors (1 and 2) binding to the open active conformation of FD. In continuation of our drug discovery program, we designed compounds applying structure-based approaches to improve interactions with FD and gain selectivity against S1 serine proteases. We report herein the design, synthesis and medicinal chemistry optimization of the benzylamine series culminating in the discovery of 12, an orally bioavailable and selective FD inhibitor. 12 demonstrated systemic suppression of AP activation in a lipopolysaccharide (LPS)-induced AP activation model, as well as local ocular suppression in intravitreal injection-induced AP activation model in mice expressing human FD.


  • Open Access

    Structure of neprilysin in complex with the active metabolite of sacubitril

    by Nikolaus Schiering, Allan D’aRcy, Frederic Villard, Paul Ramage, Claude Logel, Frederic Cumin, Gary M. Ksander, Christian Wiesmann, Rajeshri G. Karki, Muneto Mogi

    Sacubitril is an ethyl ester prodrug of LBQ657, the active neprilysin (NEP) inhibitor and a component of LCZ696 (sacubitril/valsartan). We report herein the three-dimensional structure of LBQ657 in complex with human NEP at 2 Å resolution. The crystal structure unravels the binding mode of the compound occupying the S1, S1’ and S2’ sub-pockets of the active site, consistent with a competitive inhibition mode. An induced fit conformational change upon binding of the P1’-biphenyl moiety of the inhibitor suggests an explanation for its selectivity against structurally homologous zinc metallopeptidases.